Anika Therapeutics (ANIK) Share-based Compensation (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Share-based Compensation data on file, last reported at $1.7 million in Q1 2026.

• On a quarterly basis, Share-based Compensation fell 44.67% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was -$1.0 million, a 105.22% decrease from a year earlier, with the FY2025 full-year figure at $2.8 million, down 78.39% from the prior year.
• Share-based Compensation for Q1 2026 stood at $1.7 million, up from -$4.8 million in the prior quarter.
• Over the last five years, Share-based Compensation for ANIK reached as high as $10.6 million in Q4 2024 and fell as low as -$10.5 million in Q4 2022.
• Historically, Share-based Compensation has averaged $640941.2 across 5 years, with a median of $1.7 million in 2026.
• Across the five-year window, Share-based Compensation plunged 431.21% in 2022 and surged 12921.74% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at -$10.5 million in 2022, then rose by 11.54% to -$9.3 million in 2023, then jumped by 214.35% to $10.6 million in 2024, then sank by 145.15% to -$4.8 million in 2025, then jumped by 134.6% to $1.7 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $1.7 million in Q1 2026, -$4.8 million in Q4 2025, and -$132000.0 in Q3 2025.